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cell line Vero-E6. Toxicol. In Vitro (2010), doi:1Microcystin-LR (MCLR) is a peptide produced by freshwater cyanobacteria that induces severe hepatotox-
icity in humans and animals. MCLR is also a potent tumour promoter and it has been proposed that this
activity is mediated by the inhibition of protein phosphatases PP1/PP2A, possibly through the activation
of proto-oncogenes c-jun, c-fos and c-myc. However, the mechanisms underlying MCLR-induced tumour
promotion are still largely unknown, particularly in non-liver cells. In previous studies we have demon-
strated that micromolar concentrations of MCLR induce cytotoxic effects in the kidney Vero-E6 cell line.
The purpose of the present work was to evaluate whether the exposure to subcytotoxic concentrations of
MCLR was sufﬁcient to induce the proliferation of Vero-E6 cells. Through BrdU incorporation assay we
show that at nanomolar concentrations MCLR stimulates cell cycle progression in Vero-E6 kidney cell
line. Moreover, the analysis of mitogen-activated protein kinases p38, JNK and ERK1/2 activity revealed
that the proliferative effect of MCLR is associated with the activation of the pro-proliferative ERK1/2 path-
way. These results emphasise the importance to conﬁrm in vivo the impact of MCLR on tumour promo-
tion at kidney level.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Microcystins (MC) are secondary metabolites produced by
freshwater cyanobacteria that have been associated with severe
episodes of human and animal acute hepatotoxicity (Codd et al.,
2005; van Apeldoorn et al., 2007). MC are a group of approximately
70 structural variants sharing the common cyclic heptapeptide
structure cyclo(-D-Ala1-L-X2-MeAsp3-L-Z4-Adda5-D-Glu6-N-Mdha7)
where X and Z are variable L-amino acids. MeAsp, Mdha and Adda
are abbreviations of methylaspartic acid, methyldehydroalanine
and 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-die-
noic acid, respectively (Chen et al., 2006). MCLR (with leucine-L-
and arginine-R- in the variable positions) is one of the most fre-
quent and acutely toxic variant (Funari and Testai, 2008). MC is
produced by several cyanobacteria species from distinct genera
such as Microcystis, Anabaena, Planktothrix (van Apeldoorn et al.,
2007). Under favourable environmental conditions, particularly in
eutrophic water resources, those organisms proliferate massively
forming dense biomass concentrations (bloom) that, during thell rights reserved.
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icrocystin-LR activates the ERK
0.1016/j.tiv.2010.05.018senescence phase, can release high proportions of MC into water
column/surface (van Apeldoorn et al., 2007). The ingestion of con-
taminated raw water or inefﬁciently treated drinking water is the
principal route for human exposure to MC (Codd, 2000). Human
intoxication can also occur through haemodialysis treatment if
the water that supplies the haemodialysis unit is contaminated
with toxic cyanobacteria. Although less frequent, this route is the
most harmful due to the direct enter of microcystins into the blood
stream (Codd, 2000).
The hepatotoxicity of MC is relatively well characterized both
in vivo and in vitro models (revised in Duy et al., 2000; van Apel-
doorn et al., 2007). The liver speciﬁcity of MC is due to their selec-
tive uptake by hepatocytes through the membrane transport
family OAPT – Organic Anion Polypeptide Transporters – that
mediates the uptake and elimination of numerous xenobiotics
(Hagenbuch and Meier, 2003; Fischer et al., 2005). Inside the hepa-
tocytes, MCLR inhibits the serine/threonine protein phosphatases 1
and 2A (Yoshizawa et al., 1990). The inhibition of PP1 and PP2A in-
duces the hyperphosphorylation of cytoskeletal proteins, which
leads to hepatocyte deformation, with the consequent collapse of
liver tissue organization, liver necrosis, liver haemorrhage and
death (Falconer and Yeung, 1992).
Based on animal sub-chronic toxicological data, the World
Health Organization (WHO, 2008) has established a guideline for
microcystins in drinking water (1 nM of MCLRequiv). This guideline1/2 kinases and stimulates the proliferation of the monkey kidney-derived
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logical database is limited (WHO, 2008). Besides the liver, the ef-
fects of microcystins on other organs have been barely
investigated.
In fact, although OATPs are absent, or less expressed, in most
non-liver cells (Fischer et al., 2005) some of the speciﬁc MC carriers
have been already identiﬁed in human kidney (OATPA, OATPB) and
intestine (OATPB) (Hagenbuch and Meier, 2003). In addition, some
studies described in vivo toxic effects of MCLR in the kidney (Nobre
et al., 1999; Milutinovic´ et al., 2002, 2003), intestine (Botha et al.,
2004; Gaudin et al., 2008), brain (Maidana et al., 2006), lungs
(Soares et al., 2007) and reproductive system (Ding et al., 2006).
Epidemiological data has suggested an association between hu-
man chronic exposure to low levels of microcystins in drinking
water and an increase in primary hepatocellular (Yu, 1995; Ueno
et al., 1996) and colorectal cancers (Zhou et al., 2002). However,
confounding risk factors associated with other contaminants or
organisms were not ruled out and information about the levels of
exposure is very limited (IARC, 2006). Consequently, an unequivo-
cal cause-effect relationship between human exposure tomicrocys-
tins and cancer development was not yet established. Nevertheless,
in vivo two-stage rodent carcinogenesis assays have demonstrated
that MCLR induces tumour promotion in rat liver (Nishiwaki-
Matsushima et al., 1992) and mouse skin (Falconer, 1991) and tu-
mour progression in mouse colon (Humpage et al., 2000). Based
on its tumour promoting activity, MCLR is presently classiﬁed by
IARC (2006) as a potential carcinogen to humans (class 2B).
The mechanisms underlying the MCLR-induced tumour promo-
tion are largely unknown. However, it was suggested that mito-
gen-activated protein kinases (MAPK) may be involved in the
tumourpromotionactivity ofMCLRgiven its ability to inhibit protein
phosphatases PP1 and PP2A (Gehringer, 2004). The MAPK cascade
Ras-Raf-MEK1/2-ERK1/2 has a key role in cellular proliferation and
is regulated by several types of phosphatases including the serine/
threonine phosphatases PP1 and PP2A (Junttila et al., 2008). PP2A,
in particular, has primarily an inhibitory effect on the pathway,
namely on the Ras, MEK1/2 and ERK1/2 components (Junttila et al.,
2008). Thus, it could be hypothesised that by inhibiting PP2A, MCLR
deregulates the ERK1/2 pathway and promotes cell proliferation.
The involvement of the ERK1/2 pathway in MCLR-mediated tu-
mour promotion has been supported only by few studies. Li et al.
(2009) demonstrated that an extract of microcystins puriﬁed from
a cyanobacterial bloom induced the activation the proto-onco-
genes c-jun, c-fos e c-myc in mouse liver, kidney and testis. In fact,
Fos and Jun proteins form the composite transcription factor acti-
vating protein-1 (AP-1), a mitogen-activating transactivator
important for cell proliferation (Turatti et al., 2005). It is known
that active ERK1/2 accumulates in the nucleus and activates tran-
scription factors (Elk-1 and SAP 1A) that stimulate the transcrip-
tion of c-Fos (Gilley et al., 2009) and that the activation of ERK1/
2 stimulates the activity of AP-1 complex. This induces expression
of cyclin D and promotes cell cycle progression (Chang and Karin,
2001; Fang and Richardson, 2005; Meloche and Pouysségur, 2007).
Zhu et al. (2005) have demonstrated that MCLR induces the
transformation of immortalized colorectal crypt cells through the
constitutive activation of AKT and MAPK (p38 and JNK) cascades.
This supports the hypothesis that MCLR represents a risk of colo-
rectal cancer because cellular transformation is an initial step of
carcinogenesis (Zhu et al., 2005). They also found that MCLR acti-
vates Ras and Raf, but without further effect on ERK1/2 status.
Interestingly, Komatsu et al. (2007) showed that MCLR induces
the phosphorylation of ERK1/2 on the embryonic kidney HEK293
cell line. However, this effect was associated with apoptosis and
not with cell survival and growth.
In previous studies we demonstrated that MCLR induces cyto-
toxic effects (organelle changes/damages, cell lysis, apoptosis andPlease cite this article in press as: Dias, E., et al. Microcystin-LR activates the ERK
cell line Vero-E6. Toxicol. In Vitro (2010), doi:10.1016/j.tiv.2010.05.018necrosis) on the kidney-derived Vero-E6 cell line (Alverca et al.,
2009; Dias et al., 2009). These effects were observed above 5 lM,
according to a dose and time- dependent manner. The purpose of
the present work was to evaluate the effects of low (non-cytotoxic)
levels of MCLR (0.5 nM–5 lM) on the activation status of MAP ki-
nases and on the stimulation of cell cycle progression and prolifer-
ation in the same cell line.2. Materials and methods
2.1. Microcystin-LR and cyanobacterial extracts
Microcystin-LR was purchased from Sigma-Aldrich (CAS Num-
ber 101043-37-2) as a white solid ﬁlm (purityP 95%, by HPLC).
A stock solution of MCLR (1 mM) was prepared by dissolving the
toxin in MEM cell culture medium (see following section). This
solution was sterilized by ﬁltration through 0.22 lm ﬁlters and
kept at 20 C until use. This form of MCLR is thereafter named
‘‘pure MCLR”. Work solutions were prepared by diluting this solu-
tion in MEM culture medium.
The cyanobacteria extracts were prepared from two Microcystis
aeruginosa strains (LMECYA 110 and LMECYA 127) isolated in
1996 from a natural bloom at Montargil reservoir, Portugal (Valé-
rio et al., 2009a) and successfully maintained in the laboratory as
monoalgal, free of eukaryotes, non-axenic cultures. The produc-
tion of microcystin by those strains was fully characterized by
Valério et al. (2009b). SPE-HPLC-DAD analysis of cyanobacterial
extracts was made according to International Standard ISO
20179 (2005), conﬁrming the production of MCLR by LMECYA
110 and the LMECYA 127 inability to produce microcystins. This
strain was tested as a negative control of M. aeruginosa matrix.
Cultures of both isolates were performed in 2.5 L plankton light
reactors (Aqua-Medic, Bissendorf, Germany) containing Z8 med-
ium (Skulberg and Skulberg, 1990) under continuous aeration,
in a 14/10 h L/D cycle (light intensity 16 ± 4 lE m2 s1, approx.)
at 20 ± 1 C. Cells harvested during exponential growth phase
were lyophilized in a freeze drier (Micromodul Y10, Savant, NY,
USA) and extracted with a 75% methanol solution (10 mL per
100 mg of freeze dried material) overnight at 4 C under magnetic
stirring. The extract was further sonicated with an ultrasonic
probe (Sonics Vibra-Cell CV33, Sonics & Materials Inc., CA, USA),
centrifuged and evaporated at 35 C (Buchi-R, Flawil, Switzerland)
to eliminate the alcoholic fraction. The resulting aqueous extract
was subjected to solid phase extraction for microcystin clean-up
on Sep-PakC18 cartridges (500 mg, Millipore, Bedford, MA, USA)
preconditioned with methanol and equilibrated with distilled
water. The MCLR containing fraction was eluted with methanol
(80%, v/v) and evaporated to dryness. The solid residue was re-
suspended in 50 mM acetic acid and puriﬁed by preparative chro-
matography through Bio-Gel P2 (40–90 lm, Bio-Rad Inc., CA,
USA) packed column (Amersham Biosciences, XK 26/40, i.d./
length). The mobile phase consisted of 50 mM acetic acid and
the ﬂow rate was set at 1 mL min1 (Knauner WellChrom K-120
pumps, Germany). The elution fractions (5 mL) were collected
on a fraction collector (Bio-Rad Mod. 2110, CA, USA) and analysed
by HPLC-DAD according to the ISO standard method 20179 using
commercially available MCLR standards (Alexis Biochemicals, CA,
USA). MCLR-containing fractions of LMECYA 110 and correspon-
dent fractions from LMECAY 127 were dried in a Speed-Vac sys-
tem (AES 1000, Savant), re-suspended in MEM culture medium,
sterilized through PVDF 0.22 lm syringe ﬁlters and kept at
20 C until use. Those ﬁnal extracts was further analysed by
HPLC-DAD to conﬁrm the MCLR concentration. Work solutions
were prepared by diluting the puriﬁed extracts in MEM culture
medium.1/2 kinases and stimulates the proliferation of the monkey kidney-derived
Fig. 1. Activation status of ERK1/2, p38 and JNK kinases in Vero-E6 cells by a MCLR-
producer M. aeruginosa strain (LMECYA 110). Cells were exposed for 24 h to
LMECYA 110 extract dilutions containing 5, 50, 500 and 5000 nM of MCLR. The
levels of active (phosphorylated) ERK1/2, p38 and JNK, total ERK1/2 and a-tubulin
(as loading control of JNK and p38) were detected by Western-blot. The negative
control consisted in non-treated cells. The positive controls consisted of Epidermal
Growth Factor (EGF, 10 ng mL1, 5 min) for ERK1/2 analysis and of anisomycin
(0.25 lM, 1 h) for JNK and p38 analysis. Results were obtained from two
independent experiments.
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The Vero-E6 cell line (kidney epithelial cells derived from the
African green monkey – Cercopithecus aethiops) was obtained from
the American Type Culture Collection (ATCC-CRL 1586). All media
and supplements were purchased from Invitrogen (Paisley, UK).
Cells were grown in 25 cm2 ﬂasks (Nunc, Roskilde, Denmark) in
Modiﬁed Eagle Medium (MEM) supplemented with 10% FBS,
0.1 mM non-essential aminoacids and 1 mM sodium pyruvate, in
a 5% CO2 humidiﬁed incubator at 37 C. Cells in exponential growth
phase were detached from the growth surface (trypsin, 0.5%), cen-
trifuged (300g) and the cell viability was determined by the trypan
blue dye exclusion method (Philips, 1973).
2.3. Evaluation of MCLR effect on ERK1/2 activation
2.3.1. Cell exposure to cyanobacterial extracts and pure MCLR
Vero-E6 cells were seeded in 35 mm culture dishes and cul-
tured for 24 h for cell adherence and growth. The growth medium
was replaced by serial dilutions of the LMECYA 110 extract in
fresh growth medium, corresponding to ﬁnal concentrations of
MCLR ranging from 5 to 5000 nM of MCLR. The same biomass
dilutions (from 0.56 to 556 lg mL1) of the non-toxic LMECYA
127 extract were tested in parallel as a control of M. aeruginosa
extract matrix. Serial dilutions of pure MCLR stock solution con-
taining 5–5000 nM of toxin were also tested. The cells were ex-
posed to LMECYA extracts and pure MCLR for 24 h prior to
MAPK analysis by immunoblotting (ERK1/2, P38 and JNK in cells
exposed to LMECYA 110; ERK1/2 in cells exposed to LMECYA 127
and pure MCLR). The negative control consisted of cells grown in
fresh culture medium. The positive control of the assay consisted
in cells exposed to Epidermal Growth Factor – EGF (10 ng mL1,
5 min) or anisomycin (0.25 lM, 1 h). Experiments were per-
formed in two (M. aeruginosa extracts) or three (pure MCLR) inde-
pendent experiments.
2.3.2. Cell lysis, SDS–PAGE and Western blot analysis of ERK1/2
After toxin exposure, cells were washed with PBS and lysed
with 2 Laemmli buffer. Lysates were denaturated at 95 C for
10 min and proteins were separated on 10% SDS–polyacrylamide
gels. After electrophoresis, proteins were transferred onto PVDF
(polyvinylidene diﬂuoride) membranes (Bio-Rad) and probed with
either mouse-anti-phospho-ERK1/2, anti-phospho-JNK or anti-
phospho-p38 antibodies from Sigma-Aldrich (dilution 1/500, Ma-
drid, Spain). The same membranes were stripped (200 mM NaOH,
5 min) and probed with rabbit-anti-ERK1/2 antibody (dilution 1/
1000, Cone MAPK-YT, Sigma-Aldrich) and mouse-anti-a-tubulin
(dilution 1/1000, Sigma-Aldrich) as loading controls. Speciﬁc bind-
ing was detected after incubation with goat-anti-rabbit or goat-
anti-mouse peroxidase-conjugate antibodies (dilution 1/3000,
Bio-Rad) by Enhanced ChemiLuminescence (ECL) detection.
2.4. G1/S progression assay
The effect of MCLR on cell proliferation was determined using
the BrdU assay, which is based on the measurement of incorpora-
tion of 5-bromo-2-deoxyuridine during DNA synthesis. Vero-E6
cells (2  105) were seeded on 10  10 mm cover slips placed in
35 mm culture dishes and were maintained for 24 h to allow cell
attachment and growth. Culture medium was then replaced by
toxin exposure medium supplemented with 1% of FBS and contain-
ing 0.5, 1, 5 or 10 nM of MCLR. Controls consisted of cells in culture
medium supplemented with 1% or 10% of FBS. After 23 h of expo-
sure, 60 lM BrdU (Sigma) was added for 1 h. Cells were washed
with PBS, ﬁxed in 4% (v/v) paraformaldehyde in PBS for 30 min at
4 C, permeabilized with 100% methanol for 10 min at room tem-Please cite this article in press as: Dias, E., et al. Microcystin-LR activates the ERK
cell line Vero-E6. Toxicol. In Vitro (2010), doi:10.1016/j.tiv.2010.05.018perature and then incubated with 4 N HCl for 10 min to denature
DNA. The cells were neutralized with 1 M tris, pH 8.8 and then
washed 3 with PBS. Cells on the coverslips were incubated with
the mouse-anti-BrdU primary antibody (Roche) (dilution 1/20), fol-
lowed by goat-anti-mouse secondary antibody conjugated with
Texas Red (Jackson Immunoresearch Laboratories) (dilution 1/
200). Coverslips were counterstained with Dapi (1.25 lg/mL),
post-ﬁxed with PFA, mounted on glass slides with Vectashield
mounting medium (Vector Laboratories, Berlingame, CA, USA)
and sealed with nail polish. All preparations were observed under
a Leica TCS ﬂuorescence microscope. At least 300 randomly chosen
nuclei were scored for BrdU incorporation for each sample. This
procedure was repeated in three independent experiments for
each toxin concentration.
2.5. Statistical analysis
Results were expressed as mean values ± standard deviation
(mean ± SD). Statistical analysis was performed by Student’s t-test.
Differences were considered signiﬁcant when p < 0.05.3. Results
The effect of exposure to a MCLR-containing M. aeruginosa ex-
tract on the activation state of the canonical MAP kinases p38,
JNK and ERK1/2 on Vero-E6 cells was analysed by Western-blot
using phospho-speciﬁc antibodies (Fig. 1). Interestingly, while all
the LMECYA 110 extract dilutions (containing 5, 50, 5000 and
5000 nM of MCLR) induced a marked increase of phosphorylated
ERK1/2 (p-ERK1/2 – Fig. 1), no considerable variation was found1/2 kinases and stimulates the proliferation of the monkey kidney-derived
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ﬁrm that the observed results on ERK1/2 activity were due to MCLR
exposure and not to an unknown contaminant present in the LME-
CYA 110 extract, the experiment was repeated using equivalent
dilutions of the LMECYA 127 extract and similar concentrations
of commercially available MCLR. Densitometric analysis of Wes-
tern-blots from independent experiments with M. aeruginosa ex-
tracts revealed that whereas exposure to LMECYA 110 extract
containing low concentrations of MCLR was sufﬁcient to induce a
1.71–3.66-fold increase in p-ERK1/2, with maximum effect at 50
nM, none of the dilutions of the LMECYA 127 extract produced
an effect on the activation state of ERK1/2 (Fig. 2A). A signiﬁcant
difference (p = 0.037) was found between the dose-response curves
from LMECYA 110 and LMECYA 127 extracts, witch conﬁrms the
inability of LMECYA 127 to activate ERK1/2. As shown in Fig. 2B,
the densitometric analysis of Western-blots from three indepen-
dent experiments revealed a slightly higher overall effect in p-
ERK1/2 for pure MCLR (2.8–4-fold increase). Moreover, the highestFig. 2. Activation of ERK1/2 in Vero-E6 cells exposed for 24 h to (A) M. aeruginosa
extracts LMECYA 110 (MCLR-producer strain) and LMECYA 127 (non-toxic strain);
(B) pure MCLR. The results were obtained by densitometry analysis of Western blots
and are presented as mean ± standard deviation of treated cells in relation to
negative control. In Fig. 2A, secondary x-axis represents the M. aeruginosa biomass
concentration and p indicates the signiﬁcance of the difference between the two
dose-response curves by a paired Student’s t-test. In Fig. 2B, *represents a
statistically signiﬁcant difference between treated and control cells (p < 0.05).
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tion (5 nM) then with LMECYA 110 extract. We then chose a range
of pure MCLR concentrations (0.5, 1, 5 and 10 nM) around the one
with highest ERK1/2 activation (5 nM) and evaluated its effect on
cell cycle progression of Vero-E6 cells by the G1/S transition BrdU
assay. As shown in Fig. 3, exposure of starved cells (1% FBS) to a
range of 1–10 nM of MCLR clearly promoted BrdU incorporation
(red cells) when compared to untreated starved cells (negative
control). Quantiﬁcation of the observed variations revealed a sta-
tistically signiﬁcant stimulation of G1/S progression at all three
concentrations, with a maximum 2.2-fold increase at 5 nM of
MCLR (Fig. 4).4. Discussion
In this work we demonstrated that MCLR stimulates the prolif-
eration of kidney-derived Vero-E6 cell line in the concentration
range of 1–10 nM. We showed that both pure toxin and an extract
obtained from a MCLR-producer M. aeruginosa strain had no effect
on the activation of p38 and JNK kinases but signiﬁcantly increased
ERK1/2 phosphorylation with maximum effects in the 5 and 50 nM
dose-range, respectively. This indicates that the stimulatory activ-
ity of low MCLR concentrations on Vero-E6 cell proliferation is
mediated by the activation of this MAPK pathway.
MCLR is a potent inhibitor of protein phosphatases PP1 and
PP2A (Yoshizawa et al., 1990). The key role of PP1 and PP2A in
the regulation of cell division through the modulation of phosphor-
ylation/dephosphorylation of signalling pathways have suggested
that the MCLR-induced tumour promotion is mediated by MAPK
(Gehringer, 2004).
Up to now, only few reports described the role of MAPK on
MCLR-mediated toxicity. A study from Zhu et al. (2005) demon-
strated that MCLR (0.1 nM) is able to transform immortalized colo-
rectal crypt cells (NCC), rendering them anchorage independent
and highly proliferative through the activation of the Akt and the
p38 and JNK MAPK pathways. Since the transformation of colorec-
tal cells is an important initial step in carcinogenesis (Zhu et al.,
2005), these results support the hypothesis of MCLR being a risk
factor of colorectal cancer (Zhou et al., 2002). In the same study,
it was also demonstrated that members of the Ras and Raf families
were activated, but without further activation of ERK1/2 kinases
(Zhu et al., 2005). Here we found in Vero-E6 cells that low MCLR
concentration affected the ERK1/2 but not the p38 and JNK MAPK
pathways. The non-activation of P38 and JNK should be further
conﬁrmed by testing more exposure conditions to MCLR (time of
exposure and toxin concentration). Interestingly, Komatsu et al.
(2007) also reported that MCLR induced the phosphorylation of
ERK1/2 in human embryonic kidney (HEK) 293 cells. They de-
scribed that the activation of ERK1/2 occurred at the same toxin
concentration (50 nM) that induced apoptosis and concluded that,
in this cell line, apoptosis is mediated by ERK1/2. However, the
HEK293 cells studied were transfected with the human hepatocyte
uptake transporters OATP1B1 and OATP1B3. Therefore, the toxic-
okinetics of MCLR in transfected HEK293 cells is surely quite dis-
tinct from non-OATP transfected cells, given the fact that OATP
expression in immortalized cell lines is reduced or even abolished
(Boaru et al., 2006). Hence, the putative higher toxin absorption
and accumulation in these HEK293 cells might justify their higher
sensitivity to MCLR compared with Vero-E6 cells, which presented
cytotoxic effects only for MCLR concentrations in the range of lM
(Dias et al., 2009). Moreover, our study revealed that ERK1/2 is
activated in Vero-E6 cells within a broad range of concentrations
(5 nM–5 lM) whereas cell proliferation was stimulated within
the range of 1–10 nM. As previously demonstrated, MCLR induces
autophagy in Vero-E6 cells exposed to 5 lM, followed by apoptosis1/2 kinases and stimulates the proliferation of the monkey kidney-derived
Fig. 3. Effect of pure MCLR on cell cycle progression of Vero-E6 cells. Cells were exposed to 0.5, 1, 5 and 10 nM of MCLR for 24 h under 1% FBS starvation conditions, then
incubated with BrdU, ﬁxed and stained with anti-BrdU and DAPI. Fluorescence images show BrdU incorporation into replicating nuclei in red and are representative of three
independent experiments. Negative control consisted of untreated, 1% FBS starved cells. Positive control consisted of cells grown in 10% FBS-supplemented culture medium.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
E. Dias et al. / Toxicology in Vitro xxx (2010) xxx–xxx 5above 20 lM (Alverca et al., 2009). Autophagy is a process that
eliminates damaged or redundant organelles and misfolded pro-
teins, contributing to the maintenance of cell homeostasis and sur-
vival. However, it could also function as a cell death mechanism
that might collaborate with apoptotic cell death (Codogno and
Meijer, 2005; Eskelinen and Saftig, 2009). Notably, the ERK1/2
pathway has been implicated in the positive regulation of autoph-
agy (Ogier-Nenis et al., 2000; Pattingre et al., 2003; Meijer and
Codogno, 2004) and in the inhibition of apoptosis (Junttila et al.,
2008). Thus, we hypothesise that the MCLR-mediated ERK1/2 acti-
vation has a binary effect in Vero-E6 cells: the stimulation of cell
proliferation at low MCLR concentrations and the induction of
autophagic (pre-apoptotic) mechanisms at (sub)cytotoxic concen-
trations of MCLR. The role of ERK1/2 activation on the MCLR-med-
iated autophagic response as well as its eventual contribution to
the inhibition of apoptosis would signiﬁcantly improve the knowl-
edge of the mechanisms underlying MCLR tumour promoting
activity.
Although the main target organ of MCLR is the liver and despite
most of the toxin being excreted via biliar route, a small (9%) per-Please cite this article in press as: Dias, E., et al. Microcystin-LR activates the ERK
cell line Vero-E6. Toxicol. In Vitro (2010), doi:10.1016/j.tiv.2010.05.018centage of the toxin (free or conjugated with GSH and Cys) is also
eliminated through the urine (Robinson et al., 1990; Ito et al.,
2002). It should be noted that although MCLR metabolites are less
toxic than non-metabolized toxin, they still maintain the inhibitory
activity of protein phosphatases PP1 and PP2A (Ito et al., 2002). In
this way, the nephrotoxic effects of MCLR should not be disre-
garded, in particular those related with chronic exposure to low
levels of toxin.
In conclusion, this work demonstrates that MCLR (pure or ex-
tracted from cyanobacteria) stimulates the G1/S transition of the
kidney cell line Vero-E6 at very low concentrations (circa 5000
times lower than those that induce cytotoxic effects). The degree
of ERK1/2 activation and subsequent G1/S cell cycle progression
that was observed following MCLR treatment is comparable to that
described for other tumorigenic stimuli (Moniz et al., 2007; Moniz
and Peter, 2010) and thus biologically meaningful. Considering
that the ERK1/2 pathway is known to be upregulated in approxi-
mately one-third of all human cancers (Dhillon et al., 2007), our re-
sults emphasise the importance to conﬁrm in vivo the impact of
MCLR on tumour promotion at kidney level.1/2 kinases and stimulates the proliferation of the monkey kidney-derived
Fig. 4. Quantiﬁcation of the effect of pure MCLR (0.5, 1, 5 and 10 nM) on Vero-E6
cell proliferation. BrdU incorporation was scored in at least 300 randomly chosen
nuclei per sample and repeated in three independent experiments.Bars represent
the mean percentage of replicating cells (±standard deviation). Line represents the
induced fold increase in G1/S transition, in relation to the negative control cells.
Results were obtained from three independent experiments. p indicates the
signiﬁcance of the difference between treated and control cells.
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